BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dvorak CC, Higham C, Shimano KA. Transplant-Associated Thrombotic Microangiopathy in Pediatric Hematopoietic Cell Transplant Recipients: A Practical Approach to Diagnosis and Management. Front Pediatr 2019;7:133. [PMID: 31024873 DOI: 10.3389/fped.2019.00133] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 8.7] [Reference Citation Analysis]
Number Citing Articles
1 Schoettler M, Chonat S, Williams K, Lehmann L. Emerging therapeutic and preventive approaches to transplant-associated thrombotic microangiopathy. Curr Opin Hematol 2021;28:408-16. [PMID: 34534983 DOI: 10.1097/MOH.0000000000000687] [Reference Citation Analysis]
2 Saunders IM, Tan M, Koura D, Young R. Long-term Follow-up of Hematopoietic Stem Cell Transplant Survivors: A Focus on Screening, Monitoring, and Therapeutics. Pharmacotherapy 2020;40:808-41. [PMID: 32652612 DOI: 10.1002/phar.2443] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Lia G, Giaccone L, Leone S, Bruno B. Biomarkers for Early Complications of Endothelial Origin After Allogeneic Hematopoietic Stem Cell Transplantation: Do They Have a Potential Clinical Role? Front Immunol 2021;12:641427. [PMID: 34093530 DOI: 10.3389/fimmu.2021.641427] [Reference Citation Analysis]
4 Gavriilaki E, Ho VT, Schwaeble W, Dudler T, Daha M, Fujita T, Jodele S. Role of the lectin pathway of complement in hematopoietic stem cell transplantation-associated endothelial injury and thrombotic microangiopathy. Exp Hematol Oncol 2021;10:57. [PMID: 34924021 DOI: 10.1186/s40164-021-00249-8] [Reference Citation Analysis]
5 Higham CS, Shimano KA, Melton A, Kharbanda S, Chu J, Dara J, Winestone LE, Hermiston ML, Huang JN, Dvorak CC. A pilot trial of prophylactic defibrotide to prevent serious thrombotic microangiopathy in high-risk pediatric patients. Pediatr Blood Cancer 2022;69:e29641. [PMID: 35253361 DOI: 10.1002/pbc.29641] [Reference Citation Analysis]
6 Diorio C, McNerney KO, Lambert M, Paessler M, Anderson EM, Henrickson SE, Chase J, Liebling EJ, Burudpakdee C, Lee JH, Balamuth FB, Blatz AM, Chiotos K, Fitzgerald JC, Giglia TM, Gollomp K, Odom John AR, Jasen C, Leng T, Petrosa W, Vella LA, Witmer C, Sullivan KE, Laskin BL, Hensley SE, Bassiri H, Behrens EM, Teachey DT. Evidence of thrombotic microangiopathy in children with SARS-CoV-2 across the spectrum of clinical presentations. Blood Adv 2020;4:6051-63. [PMID: 33290544 DOI: 10.1182/bloodadvances.2020003471] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 14.5] [Reference Citation Analysis]
7 Diorio C, Shraim R, Vella LA, Giles JR, Baxter AE, Oldridge DA, Canna SW, Henrickson SE, McNerney KO, Balamuth F, Burudpakdee C, Lee J, Leng T, Farrel A, Lambert MP, Sullivan KE, Wherry EJ, Teachey DT, Bassiri H, Behrens EM. Proteomic profiling of MIS-C patients indicates heterogeneity relating to interferon gamma dysregulation and vascular endothelial dysfunction. Nat Commun 2021;12:7222. [PMID: 34893640 DOI: 10.1038/s41467-021-27544-6] [Reference Citation Analysis]
8 Stallworth JY, Horton JC. Massive periorbital edema following hematopoietic stem cell transplantation. American Journal of Ophthalmology Case Reports 2022. [DOI: 10.1016/j.ajoc.2022.101559] [Reference Citation Analysis]
9 Han Y. [How I treat transplant-associated thrombotic microangiopathy]. Zhonghua Xue Ye Xue Za Zhi 2020;41:272-5. [PMID: 32447928 DOI: 10.3760/cma.j.issn.0253-2727.2020.04.002] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
10 Dandoy CE, Rotz S, Alonso PB, Klunk A, Desmond C, Huber J, Ingraham H, Higham C, Dvorak CC, Duncan C, Schoettler M, Lehmann L, Cancio M, Killinger J, Davila B, Phelan R, Mahadeo KM, Khazal S, Lalefar N, Vissa M, Myers K, Wallace G, Nelson A, Khandelwal P, Bhatla D, Gloude N, Anderson E, Huo J, Roehrs P, Auletta JJ, Chima R, Lane A, Davies SM, Jodele S. A pragmatic multi-institutional approach to understanding transplant-associated thrombotic microangiopathy after stem cell transplant. Blood Adv 2021;5:1-11. [PMID: 33570619 DOI: 10.1182/bloodadvances.2020003455] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
11 Young JA, Pallas CR, Knovich MA. Transplant-associated thrombotic microangiopathy: theoretical considerations and a practical approach to an unrefined diagnosis. Bone Marrow Transplant 2021;56:1805-17. [PMID: 33875812 DOI: 10.1038/s41409-021-01283-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Jodele S, Dandoy CE, Lane A, Laskin BL, Teusink-Cross A, Myers KC, Wallace G, Nelson A, Bleesing J, Chima RS, Hirsch R, Ryan TD, Benoit S, Mizuno K, Warren M, Davies SM. Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab. Blood 2020;135:1049-57. [PMID: 31932840 DOI: 10.1182/blood.2019004218] [Cited by in Crossref: 14] [Cited by in F6Publishing: 29] [Article Influence: 7.0] [Reference Citation Analysis]
13 Sabulski A, Arcuri G, Szabo S, Care MM, Dandoy CE, Davies SM, Jodele S. Cerebral vascular injury in transplant-associated thrombotic microangiopathy. Blood Adv 2022;6:4310-9. [PMID: 35877136 DOI: 10.1182/bloodadvances.2022007453] [Reference Citation Analysis]
14 Jarmoliński T, Rosa M, Puziewicz-Zmonarska A, Kałwak K. Short Course of Eculizumab May Be Effective in Dialysis-Dependent Transplantation-Associated Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplantation: A Case Report. Transplant Proc 2020;52:2544-7. [PMID: 32917392 DOI: 10.1016/j.transproceed.2020.08.040] [Reference Citation Analysis]
15 Kaya Z, Yüce D, Kirkiz S, Koçak Ü, Ozmen F. Prognostic role of serum cytokines and soluble HLA-G levels in children with leukemia who undergo allogeneic stem cell transplantation. Cytokine 2022;153:155869. [DOI: 10.1016/j.cyto.2022.155869] [Reference Citation Analysis]
16 Hildebrandt GC, Chao N. Endothelial cell function and endothelial-related disorders following haematopoietic cell transplantation. Br J Haematol 2020;190:508-19. [PMID: 32319084 DOI: 10.1111/bjh.16621] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
17 Jodele S, Sabulski A. Transplant-associated thrombotic microangiopathy: elucidating prevention strategies and identifying high-risk patients. Expert Rev Hematol 2021;14:751-63. [PMID: 34301169 DOI: 10.1080/17474086.2021.1960816] [Reference Citation Analysis]
18 Shimizu S, Morohashi T, Kanezawa K, Yagasaki H, Takahashi S, Morioka I. Case Report: Successful Treatment With Anti-C5 Monoclonal Antibody in a Japanese Adolescent Who Developed Thrombotic Microangiopathy After Autologous Bone Marrow Transplantation for Malignant Lymphoma. Front Pediatr 2022;10:908183. [DOI: 10.3389/fped.2022.908183] [Reference Citation Analysis]
19 Elfeky R, Lucchini G, Lum SH, Ottaviano G, Builes N, Nademi Z, Battersby A, Flood T, Owens S, Cant AJ, Young H, Greener S, Walsh P, Kavanagh D, Annavarapu S, Rao K, Amrolia P, Chiesa R, Worth A, Booth C, Skinner R, Doncheva B, Standing J, Gennery AR, Qasim W, Slatter M, Veys P. New insights into risk factors for transplant-associated thrombotic microangiopathy in pediatric HSCT. Blood Adv 2020;4:2418-29. [PMID: 32492158 DOI: 10.1182/bloodadvances.2019001315] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
20 Blasco M, Guillén-Olmos E, Diaz-Ricart M, Palomo M. Complement Mediated Endothelial Damage in Thrombotic Microangiopathies. Front Med (Lausanne) 2022;9:811504. [PMID: 35547236 DOI: 10.3389/fmed.2022.811504] [Reference Citation Analysis]
21 Rozen L, Noubouossie DF, Dedeken L, Lê PQ, Ferster A, Demulder A. Is There Any Improvement of the Coagulation Imbalance in Sickle Cell Disease after Hematopoietic Stem Cell Transplantation? J Clin Med 2019;8:E1796. [PMID: 31717804 DOI: 10.3390/jcm8111796] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
22 Scordo M, Giralt S. Compliments to complement blockade for TA-TMA. Blood 2020;135:981-3. [PMID: 32219351 DOI: 10.1182/blood.2020005040] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
23 Scordo M, Giralt SA. A key step towards setting a benchmark for tackling transplant‐associated thrombotic microangiopathy. Br J Haematol 2020;189:1006-9. [DOI: 10.1111/bjh.16507] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Mezö B, Horváth O, Sinkovits G, Veszeli N, Kriván G, Prohászka Z. Validation of Early Increase in Complement Activation Marker sC5b-9 as a Predictive Biomarker for the Development of Thrombotic Microangiopathy After Stem Cell Transplantation. Front Med (Lausanne) 2020;7:569291. [PMID: 33117830 DOI: 10.3389/fmed.2020.569291] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
25 Hematopoietic Stem Cell Application Group, Chinese Society of Hematology, Chinese Medical Association. [Chinese consensus on the diagnosis and management of transplant-associated thrombotic microangiopathy (2021)]. Zhonghua Xue Ye Xue Za Zhi 2021;42:177-84. [PMID: 33910301 DOI: 10.3760/cma.j.issn.0253-2727.2021.03.001] [Reference Citation Analysis]
26 Kirkpatrick EC. Pulmonary Hypertension as a Complication of Pediatric Cancer. Glob Pediatr Health 2021;8:2333794X211009094. [PMID: 33889681 DOI: 10.1177/2333794X211009094] [Reference Citation Analysis]
27 Laberko A, Aksenova M, Shipitsina I, Khamin I, Shcherbina A, Balashov D, Maschan A. Serious Hemorrhagic Complications After Successful Treatment of Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy With Defibrotide in Pediatric Patient With Myelodysplastic Syndrome. Front Pediatr 2020;8:155. [PMID: 32432059 DOI: 10.3389/fped.2020.00155] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
28 Jodele S, Dandoy CE, Sabulski A, Koo J, Lane A, Myers KC, Wallace G, Chima RS, Teusink-cross A, Hirsch R, Ryan TD, Benoit S, Davies SM. TA-TMA risk stratification: is there a window of opportunity to improve outcomes? Transplantation and Cellular Therapy 2022. [DOI: 10.1016/j.jtct.2022.04.019] [Reference Citation Analysis]
29 Jodele S, Medvedovic M, Luebbering N, Chen J, Dandoy CE, Laskin BL, Davies SM. Interferon-complement loop in transplant-associated thrombotic microangiopathy. Blood Adv 2020;4:1166-77. [PMID: 32208488 DOI: 10.1182/bloodadvances.2020001515] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 16.0] [Reference Citation Analysis]
30 Higham CS, Collins G, Shimano KA, Melton A, Kharbanda S, Winestone LE, Huang JN, Dara J, Long-Boyle JR, Dvorak CC. Transplant-associated thrombotic microangiopathy in pediatric patients: pre-HSCT risk stratification and prophylaxis. Blood Adv 2021;5:2106-14. [PMID: 33877298 DOI: 10.1182/bloodadvances.2020003988] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
31 Betzmann D, Döring M, Blumenstock G, Erdmann F, Grabow D, Lang P, Binder G. Impact of serum insulin-like growth factor-1 on HSCT outcome in pediatric cancer patients. Transplant Cell Ther 2022:S2666-6367(22)01195-2. [PMID: 35405367 DOI: 10.1016/j.jtct.2022.03.027] [Reference Citation Analysis]
32 Abou‐ismail MY, Kapoor S, Citla Sridhar D, Nayak L, Ahuja S. Thrombotic microangiopathies: An illustrated review. Res Pract Thromb Haemost 2022;6. [DOI: 10.1002/rth2.12708] [Reference Citation Analysis]
33 Cao XY, Qiu LY, Zhang JP, Xiong M, Zhao YL, Lu Y, Zhou JR, Wei ZJ, Sun RJ, Liu DY, Zhang X, Yang JF, Lu PH. [CART therapy followed by allo-HSCT for patients with B-cell acute lymphoblastic leukemia relapsing after the first hematopoietic stem cell transplantation]. Zhonghua Xue Ye Xue Za Zhi 2021;42:318-23. [PMID: 33979977 DOI: 10.3760/cma.j.issn.0253-2727.2021.04.009] [Reference Citation Analysis]
34 Chan WYK, Ma ALT, Chan EYH, Kan ANC, Ng WF, Lee PPW, Cheuk DKL, Chiang AKS, Leung W, Chan GCF. Epidemiology and outcomes of pediatric transplant-associated thrombotic microangiopathy in Hong Kong. Pediatr Transplant 2022;:e14366. [PMID: 35860972 DOI: 10.1111/petr.14366] [Reference Citation Analysis]
35 Gloude NJ, Dandoy CE, Davies SM, Myers KC, Jordan MB, Marsh RA, Kumar A, Bleesing J, Teusink-Cross A, Jodele S. Thinking Beyond HLH: Clinical Features of Patients with Concurrent Presentation of Hemophagocytic Lymphohistiocytosis and Thrombotic Microangiopathy. J Clin Immunol 2020;40:699-707. [PMID: 32447592 DOI: 10.1007/s10875-020-00789-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
36 Ramgopal A, Sridar S, Dalal J, Kalpatthi R. Thrombotic Microangiopathy: Multi-Institutional Review of Pediatric Patients Who Underwent HSCT. J Pers Med 2021;11:467. [PMID: 34070379 DOI: 10.3390/jpm11060467] [Reference Citation Analysis]
37 Gasior Kabat M, Bueno D, Sisinni L, De Paz R, Mozo Y, Perona R, Arias-Salgado EG, Rosich B, Marcos A, Romero AB, Constanzo A, Jiménez-Yuste V, Pérez-Martínez A. Selective T-cell depletion targeting CD45RA as a novel approach for HLA-mismatched hematopoietic stem cell transplantation in pediatric nonmalignant hematological diseases. Int J Hematol 2021;114:116-23. [PMID: 33772729 DOI: 10.1007/s12185-021-03138-2] [Reference Citation Analysis]